Skip to content

Clinical study for the effect of Combinative Treatment of Heart and Spleen on intestinal flora in patients with non-st-segment elevation myocardial infarction with qi deficiency and blood stasis

Clinical study for the effect of Combinative Treatment of Heart and Spleen on intestinal flora in patients with non-st-segment elevation myocardial infarction with qi deficiency and blood stasis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029226
Enrollment
Unknown
Registered
2020-01-19
Start date
2020-01-01
Completion date
Unknown
Last updated
2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart cardiovascular disease

Interventions

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) consistent with NSTEMI diagnosis; (2) Aged 40 to 60 years; (3) patients should meet the diagnosis of TCM qi deficiency and blood stasis syndrome; (4) the cardiac function I and II level (NYHA heart function classification); (5) the patients did not take antibiotics, steroids, laxatives, antidiarrheals or probiotics within 3 months before enrollment; (6) the subject is informed and signs the informed consent voluntarily; (7) patients in cardiovascular ward.

Exclusion criteria

Exclusion criteria: (1) renal insufficiency, male serum creatinine >2.5 mg/dl (>220umo/l) female serum creatinine 2.0 mg/dl (>175umo/l); (2) significant liver disease or ALT and AST were 3 times higher than the normal upper limit; (3) after control, systolic blood pressure >160mmHg or diastolic blood pressure >100mmHg (patients should sit for at least 5 minutes before blood pressure measurement); (4) diabetic patients with random blood glucose >=13.7mmol/L or hemoglobin ALC >=9.5%; (5) women who are pregnant or preparing to be pregnant, women who are nursing, and those who are allergic to the known components of the drug; (6) patients with acute cerebrovascular disease; (7) malignant tumor or life expectancy of the patient is less than 1 year; (8) patients with severe hematopoietic system diseases; (9) severe mental illness.

Design outcomes

Primary

MeasureTime frame
CRP;

Secondary

MeasureTime frame
blood routine examination;routine urianlysis;Routine detection of feces;renal function;

Countries

China

Contacts

Public ContactWang Peili

Xiyuan Hospital, China Academy of Chinese Medical Sciences

659224730@qq.com+86 17710032820

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026